



# CEE UPDATES

April 2025

## UPCOMING EVENT:

### HTAsiaLink pre-conference patient involvement workshop

19 August 2025, 8:30 AM to 1:30 PM  
Singapore Expo

#### Voices to Action – The value of involving patients in HTA



**FIONA PEARCE**

Senior Advisor, ACE;  
Co-Chair, HTAI Patient  
and Citizen Involvement  
in HTA Interest Group  
(PCIG)



**SIMON FIFER**

HTAI PCIG;  
Director, Community  
and Patient Preference  
Research (CaPPRe)



**ANN SINGLE**

Vice President, HTAI;  
CEO, Patient Voice  
Initiative (Australia);  
HTAI PCIG Outgoing  
Chair

This workshop is being jointly organised by ACE and the Health Technology Assessment International (HTAI) Patient and Citizen Involvement in HTA Interest Group (PCIG). It aims to bring together patients from across the Asia Pacific region to explore approaches to patient involvement, identify strategies to overcome barriers to implementation, and learn about innovative methods being used to capture patient perspectives in HTA.



Scan or click on  
the QR code to  
register



## NEW HTA LEARNING MODULE FOR PATIENTS AND THE PUBLIC

The CEE team has developed a new learning module on “**How is health technology assessment (HTA) done?**” This module provides an overview of the types of information used as HTA evidence and the steps involved in an HTA. It also includes a simple quiz to reinforce key concepts. Stay tuned for more learning modules coming soon!



**CLICK HERE**

To download the module

## PATIENT EDUCATION AIDS

# 2

### Patient education aids published in March 2025

- Coronary heart disease
- Myths and facts about antiplatelet medicines for chronic coronary heart disease

Patient education aids are co-developed with patient organisations and clinicians to support the implementation of ACE Clinical Guidances by providing patients with basic information about different health conditions, treatments, medical tests and tips for better self-management.

We would like to thank members from the patient organisations for their valuable input.



Find out more




## PATIENT FACTSHEETS

5

Patient factsheets published since February 2025

- Inhalers for treating chronic obstructive pulmonary disease **(new)**
- Hormone therapy for advanced prostate cancer **(updated)**
- Inhalers for treating asthma **(updated)**
- Treatments for chronic lymphocytic leukaemia **(updated)**
- What are cell, tissue and gene therapy products? **(updated)**



Find out more



## PLAIN ENGLISH SUMMARIES

NEW



11

Plain English summaries published since February 2025

Plain English summaries (PES) provide brief information about the treatments and conditions that have been evaluated by ACE and describe the key funding recommendations made by the MOH advisory committees.

Find out more



### Published PES

#### New:

- Deucravacitinib for treating moderate-to-severe chronic plaque psoriasis
- Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
- Glofitamab for previously treated relapsed or refractory diffuse large B-cell lymphoma
- Pembrolizumab for treating advanced HER2-positive gastric cancer
- Pembrolizumab for treating non-small-cell lung cancer before and after lung surgery
- Pneumococcal conjugate vaccines for preventing pneumococcal disease in adults

- Recombinant zoster vaccine for preventing shingles and related nerve pain
- Sacituzumab govitecan for previously treated HR-positive, HER2-negative advanced breast cancer
- Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease

#### Updated:

- Chimeric antigen receptor T-cell therapies for relapsed or refractory large B-cell lymphoma
- Dostarlimab for treating primary advanced or recurrent endometrial cancer

## PATIENT INPUT

Over


# 250

**Patient responses were gathered for topics presented to the MOH advisory committees in March 2025**



The effort put in by patients to share their experiences is appreciated and every input is valuable to ACE and MOH. The CEE team notifies patient organisations of the advisory committees' funding recommendations after each meeting and provides feedback on which information provided by patients was most helpful to inform the committees' deliberations. The CEE team also invites suggestions on how the patient involvement processes can be improved through this [link](#).

## SHARING ABOUT HTA AND PATIENT ENGAGEMENT



### **Patient Engagement (PE) 101 Series - Understanding Health Technology Assessment (HTA): How Patients Can Shape Healthcare Decisions, 26 February 2025**

Ms Fiona Pearce (ACE Senior Advisor and HTAi PCIG Co-Chair) and Dr Ritu Jain (DEBRA Singapore President and ACE Consumer Panel Co-Chair) discussed HTA's role in healthcare funding and how patient engagement impacts HTA outcomes in a recent Patient Focused Medicines Development (PFMD) webinar series. Community leaders from the Asia-Pacific region also shared examples of how patient input has improved treatment access. The session recording is now available [online](#).



The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance and education.

The Consumer Engagement and Education (CEE) team supports patient involvement in ACE's work and co-develops plain English summaries and educational resources with patient organisations to improve health literacy and encourage shared healthcare decision-making between patients and their doctors.

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore.

**Published on 30 April 2025.** To find out more about ACE, scan the QR code or visit [www.ace-hta.gov.sg](http://www.ace-hta.gov.sg). You can also follow us on social media at:

